Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MIMEDX GROUP, INC.

(MDXG)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Brian Martin, Martin P. Hall, Jr. and Thomas E. Johnston completed the acquisition of Stability Biologics, LLC from MiMedx Group, Inc. for $21.2 million.

09/30/2017 EDT

Brian Martin, Martin P. Hall, Jr. and Thomas E. Johnston entered into a membership interest purchase agreement to acquire Stability Biologics, LLC from MiMedx Group, Inc. (NasdaqCM:MDXG) on August 18, 2017. The consideration includes $21.2 million net of transaction costs and a promissory note issued by Stability Biologics in the principal amount of $3.5 million in favor of MiMedx, and a waiver by the former stockholders of Stability Inc. of all claims and rights to any earn-out consideration mentioned under the January 13, 2016 agreement. At closing, MiMedx shall deliver a payment in an amount equal to $0.05 million to Stability in order to provide Stability with working capital after closing. The transaction is subject to conditions including each of Brian Martin, Thomas Johnston and Martin P. Hall, Jr. shall have executed and delivered a restrictive covenant agreement with MiMedx, Stability shall have executed and delivered to MiMedx a transition services agreement, Stability shall have executed and delivered to MiMedx a private label distributor agreement and distributor agreement pursuant to which Stability will purchase and sell MiMedx products and MiMedx shall have caused to be delivered the resignations of all officers of Stability. The transaction is expected to be completed in the third quarter of 2017. The transaction is expected to be accretive to GAAP earnings by $0.02 per fully diluted common share on an annualized basis. David W. Ghegan of Troutman Sanders LLP acted as legal advisor for MiMedx Group, Inc. A. Josef DeLisle of Miller & Martin PLLC acted as legal advisor for Stability, Brian Martin, Martin P. Hall, Jr. and Thomas E. Johnston. Rich Cockrell of Cockrell Group acted as public relations advisor for MiMedx. Brian Martin, Martin P. Hall, Jr. and Thomas E. Johnston completed the acquisition of Stability Biologics, LLC from MiMedx Group, Inc. (NasdaqCM:MDXG) for $21.2 million on September 30, 2017.


ę S&P Capital IQ 2017
All news about MIMEDX GROUP, INC.
09/14MIMEDX : HC Wainwright Adjusts Price Target for MiMedx Group to $8.50 From $20, Maintains ..
MT
09/13US Stocks Start Week Mostly Higher; Blue Chips Lead While Nasdaq Lags
MT
09/13Health Care Stocks Still Adding to Afternoon Slide
MT
09/13Top Midday Decliners
MT
09/13Health Care Stocks Slipping Monday Afternoon
MT
09/13MIMEDX : Amniotic Tissue Failed to Meet Primary Endpoints in Two Trials; Shares Plunge
MT
09/13Health Care Stocks Up Slightly in Premarket Monday Activity
MT
09/13Top Premarket Decliners
MT
09/13MIMEDX : Initial Review of Phase 3 Plantar Fasciitis Trial Data Does Not Support a Biologi..
PU
09/13MIMEDX GROUP, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K..
AQ
More news
Analyst Recommendations on MIMEDX GROUP, INC.
More recommendations
Financials (USD)
Sales 2021 251 M - -
Net income 2021 -30,3 M - -
Net Debt 2021 - - -
P/E ratio 2021 -21,8x
Yield 2021 -
Capitalization 659 M 659 M -
Capi. / Sales 2021 2,63x
Capi. / Sales 2022 2,43x
Nbr of Employees 735
Free-Float 96,4%
Chart MIMEDX GROUP, INC.
Duration : Period :
MiMedx Group, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MIMEDX GROUP, INC.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 5,95 $
Average target price 16,17 $
Spread / Average Target 172%
EPS Revisions
Managers and Directors
Timothy R. Wright Chief Executive Officer & Director
Peter M. Carlson Chief Financial Officer
M. Kathleen Behrens Wilsey Chairman
David H. Mason Chief Medical Officer
Robert Benjamin Stein Executive Vice President-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
MIMEDX GROUP, INC.-35.35%650
MODERNA, INC.305.22%170 876
GILEAD SCIENCES, INC.21.80%88 970
BIONTECH SE315.86%81 878
WUXI APPTEC CO., LTD.35.75%69 413
REGENERON PHARMACEUTICALS32.66%66 632